

World Journal of *Clinical Cases*

World J Clin Cases 2021 June 26; 9(18): 4460-4880



OPINION REVIEW

- 4460 Surgery for pancreatic tumors in the midst of COVID-19 pandemic

Kato H, Asano Y, Arakawa S, Ito M, Kawabe N, Shimura M, Hayashi C, Ochi T, Yasuoka H, Higashiguchi T, Kondo Y, Nagata H, Horiguchi A

REVIEW

- 4467 Roles of exosomes in diagnosis and treatment of colorectal cancer

Umwali Y, Yue CB, Gabriel ANA, Zhang Y, Zhang X

MINIREVIEWS

- 4480 Dynamics of host immune responses to SARS-CoV-2

Taherkhani R, Taherkhani S, Farshadpour F

- 4491 Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

Laiwatthanapaisan R, Sirinawasatien A

- 4500 Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine

Huang CT, Liang YJ

- 4506 Roles of vitamin A in the regulation of fatty acid synthesis

Yang FC, Xu F, Wang TN, Chen GX

ORIGINAL ARTICLE**Basic Study**

- 4520 Identification of the circRNA-miRNA-mRNA regulatory network and its prognostic effect in colorectal cancer

Yin TF, Zhao DY, Zhou YC, Wang QQ, Yao SK

- 4542 Tetramethylpyrazine inhibits proliferation of colon cancer cells *in vitro*

Li H, Hou YX, Yang Y, He QQ, Gao TH, Zhao XF, Huo ZB, Chen SB, Liu DX

Case Control Study

- 4553 Significance of highly phosphorylated insulin-like growth factor binding protein-1 and cervical length for prediction of preterm delivery in twin pregnancies

Lan RH, Song J, Gong HM, Yang Y, Yang H, Zheng LM

Retrospective Cohort Study

- 4559** Expected outcomes and patients' selection before chemoembolization—"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results
Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M

Retrospective Study

- 4573** Application of intelligent algorithms in Down syndrome screening during second trimester pregnancy
Zhang HG, Jiang YT, Dai SD, Li L, Hu XN, Liu RZ
- 4585** Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma
Nan YY, Zhang WJ, Huang DH, Li QY, Shi Y, Yang T, Liang XP, Xiao CY, Guo BL, Xiang Y
- 4599** Efficacy of combination of localized closure, ethacridine lactate dressing, and phototherapy in treatment of severe extravasation injuries: A case series
Lu YX, Wu Y, Liang PF, Wu RC, Tian LY, Mo HY
- 4607** Observation and measurement of applied anatomical features for thoracic intervertebral foramen puncture on computed tomography images
Wang R, Sun WW, Han Y, Fan XX, Pan XQ, Wang SC, Lu LJ
- 4617** Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases
Jin CB, Yang L
- 4627** Diagnostic value of amygdala volume on structural magnetic resonance imaging in Alzheimer's disease
Wang DW, Ding SL, Bian XL, Zhou SY, Yang H, Wang P
- 4637** Comparison of ocular axis and corneal diameter between entropion and non-entropion eyes in children with congenital glaucoma
Wang Y, Hou ZJ, Wang HZ, Hu M, Li YX, Zhang Z

Observational Study

- 4644** Risk factors for postoperative delayed gastric emptying in ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Cui GX, Wang ZJ, Zhao J, Gong P, Zhao SH, Wang XX, Bai WP, Li Y
- 4654** Clinical characteristics, gastrointestinal manifestations and outcomes of COVID-19 patients in Iran; does the location matters?
Mokarram P, Dalivand MM, Pizuorno A, Aligolighasemabadi F, Sadeghdoust M, Sadeghdoust E, Aduli F, Oskrochi G, Brim H, Ashktorab H
- 4668** AWGS2019 vs EWGSOP2 for diagnosing sarcopenia to predict long-term prognosis in Chinese patients with gastric cancer after radical gastrectomy
Wu WY, Dong JJ, Huang XC, Chen ZJ, Chen XL, Dong QT, Bai YY

Prospective Study

- 4681** Clinical outcomes and 5-year follow-up results of keratosis pilaris treated by a high concentration of glycolic acid
Tian Y, Li XX, Zhang JJ, Yun Q, Zhang S, Yu JY, Feng XJ, Xia AT, Kang Y, Huang F, Wan F

Randomized Controlled Trial

- 4690** Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks
Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH

SYSTEMATIC REVIEWS

- 4700** Mesenteric ischemia in COVID-19 patients: A review of current literature
Kerawala AA, Das B, Solangi A
- 4709** Role of theories in school-based diabetes care interventions: A critical review
An RP, Li DY, Xiang XL

CASE REPORT

- 4721** Alport syndrome combined with lupus nephritis in a Chinese family: A case report
Liu HF, Li Q, Peng YQ
- 4728** Botulinum toxin injection for Cockayne syndrome with muscle spasticity over bilateral lower limbs: A case report
Hsu LC, Chiang PY, Lin WP, Guo YH, Hsieh PC, Kuan TS, Lien WC, Lin YC
- 4734** Meigs' syndrome caused by granulosa cell tumor accompanied with intrathoracic lesions: A case report
Wu XJ, Xia HB, Jia BL, Yan GW, Luo W, Zhao Y, Luo XB
- 4741** Primary mesonephric adenocarcinoma of the fallopian tube: A case report
Xie C, Shen YM, Chen QH, Bian C
- 4748** Pancreas-preserving duodenectomy for treatment of a duodenal papillary tumor: A case report
Wu B, Chen SY, Li Y, He Y, Wang XX, Yang XJ
- 4754** Pheochromocytoma with abdominal aortic aneurysm presenting as recurrent dyspnea, hemoptysis, and hypotension: A case report
Zhao HY, Zhao YZ, Jia YM, Mei X, Guo SB
- 4760** Minimally invasive removal of a deep-positioned cannulated screw from the femoral neck: A case report
Yang ZH, Hou FS, Yin YS, Zhao L, Liang X
- 4765** Splenic Kaposi's sarcoma in a human immunodeficiency virus-negative patient: A case report
Zhao CJ, Ma GZ, Wang YJ, Wang JH

- 4772 Neonatal syringocystadenoma papilliferum: A case report
Jiang HJ, Zhang Z, Zhang L, Pu YJ, Zhou N, Shu H
- 4778 Disappeared intralenticular foreign body: A case report
Xue C, Chen Y, Gao YL, Zhang N, Wang Y
- 4783 Femoral neck stress fractures after trampoline exercise: A case report
Nam DC, Hwang SC, Lee EC, Song MG, Yoo JI
- 4789 Collision carcinoma of the rectum involving neuroendocrine carcinoma and adenocarcinoma: A case report
Zhao X, Zhang G, Li CH
- 4797 Therapeutic effect of autologous concentrated growth factor on lower-extremity chronic refractory wounds: A case report
Liu P, Liu Y, Ke CN, Li WS, Liu YM, Xu S
- 4803 Cutaneous myiasis with eosinophilic pleural effusion: A case report
Fan T, Zhang Y, Lv Y, Chang J, Bauer BA, Yang J, Wang CW
- 4810 Severe hematuria due to vesical varices in a patient with portal hypertension: A case report
Wei ZJ, Zhu X, Yu HT, Liang ZJ, Gou X, Chen Y
- 4817 Rare coexistence of multiple manifestations secondary to thalamic hemorrhage: A case report
Yu QW, Ye TF, Qian WJ
- 4823 Anderson-Fabry disease presenting with atrial fibrillation as earlier sign in a young patient: A case report
Kim H, Kang MG, Park HW, Park JR, Hwang JY, Kim K
- 4829 Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report
Leão I, Marinho J, Costa T
- 4837 Central pontine myelinolysis mimicking glioma in diabetes: A case report
Shi XY, Cai MT, Shen H, Zhang JX
- 4844 Microscopic transduodenal excision of an ampullary adenoma: A case report and review of the literature
Zheng X, Sun QJ, Zhou B, Jin M, Yan S
- 4852 Growth hormone cocktail improves hepatopulmonary syndrome secondary to hypopituitarism: A case report
Ji W, Nie M, Mao JF, Zhang HB, Wang X, Wu XY
- 4859 Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report
Łącki S, Wyżgolik K, Nicze M, Georgiew-Nadziakiewicz S, Chudek J, Wdowiak K

- 4866** Adult rhabdomyosarcoma originating in the temporal muscle, invading the skull and meninges: A case report
Wang GH, Shen HP, Chu ZM, Shen J
- 4873** *Listeria monocytogenes* bacteremia in a centenarian and pathogen traceability: A case report
Zhang ZY, Zhang XA, Chen Q, Wang JY, Li Y, Wei ZY, Wang ZC

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Shingo Tsujinaka, MD, PhD, Assistant Professor, Senior Lecturer, Surgeon, Department of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan. tsujinakas@omiya.jichi.ac.jp

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases (WJCC, World J Clin Cases)* is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for *WJCC* as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3. The *WJCC*'s CiteScore for 2019 is 0.3 and Scopus CiteScore rank 2019: General Medicine is 394/529.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ji-Hong Lin*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lai Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Dennis A Bloomfield, Sandro Vento, Bao-Gan Peng

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

June 26, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Prospective Study

Clinical outcomes and 5-year follow-up results of keratosis pilaris treated by a high concentration of glycolic acid

Yan Tian, Xiao-Xin Li, Jiao-Jiao Zhang, Qing Yun, Si Zhang, Jia-Yi Yu, Xue-Jiao Feng, Ai-Ting Xia, Yang Kang, Feng Huang, Fang Wan

ORCID number: Yan Tian 0000-0002-7078-9030; Xiao-Xin Li 0000-0002-0595-671X; Jiao-Jiao Zhang 0000-0002-8385-6757; Qing Yun 0000-0003-0163-6126; Si Zhang 0000-0002-0621-4494; Jia-Yi Yu 0000-0002-3671-713X; Xue-Jiao Feng 0000-0003-2752-6267; Ai-Ting Xia 0000-0003-2697-4068; Yang Kang 0000-0002-4883-6355; Feng Huang 0000-0002-9311-5311; Fang Wan 0000-0002-7062-7103.

Author contributions: Tian Y and Li XX contributed equally to this work, and are co-first authors; Tian Y contributed to the conception of the study; Tian Y and Li XX contributed significantly to analysis and manuscript preparation; Li XX performed the data analyses and wrote the manuscript; Zhang JJ, Yu JY and Feng XJ are responsible for the treatment process; Yun Q, Zhang S, Xia AT, Kang Y, Huang F, and Wan F helped perform the analysis with constructive discussions.

Institutional review board

statement: The study was reviewed and approved by the Institutional Review Board of the Air Force Characteristic Medical Center (Approval No. 2020-160-PJ01).

Clinical trial registration statement:

Yan Tian, Xiao-Xin Li, Jiao-Jiao Zhang, Qing Yun, Si Zhang, Jia-Yi Yu, Xue-Jiao Feng, Ai-Ting Xia, Feng Huang, Fang Wan, Department of Dermatology, Air Force Characteristic Medical Center, Beijing 100142, China

Yang Kang, Center of Medical and Health, Unit 71901 of PLA, Liaocheng 252000, Shandong Province, China

Corresponding author: Yan Tian, MD, PhD, Chief Doctor, Professor, Department of Dermatology, Air Force Characteristic Medical Center, No. 30 Fucheng Road, Haidian District, Beijing 100142, China. tianyan311@126.com

Abstract

BACKGROUND

Keratosis pilaris is a hereditary abnormal keratosis of the hair follicle orifice. Gray-brown keratotic plugs in the pores and dark red keratotic papules at the openings of hair follicles can be seen, which contain coiled hair and are often accompanied by perifollicular erythema and pigmentation. Glycolic acid can correct the abnormalities of hair follicular duct keratosis and eliminate excessive accumulation of keratinocytes. It also promotes skin metabolism and accelerates the melanin metabolism. The therapeutic effect is related to the glycolic acid concentration.

AIM

To evaluate the efficacy and safety of a high concentration of glycolic acid in the treatment of keratosis pilaris, and to observe the outcomes at 5-year of follow-up.

METHODS

Twenty-five participants were recruited and areas with typical keratosis pilaris were selected as testing sites. High concentrations of glycolic acid (50% or 70%) were applied to a circular area ($d = 8 \text{ cm}$, $S = 50 \text{ cm}^2$) and repeated four times, on days 0, 20, 40 and 60. Before each treatment and 20 d after the last treatment, on days 0, 20, 40, 60, and 80 and at a 5-year follow-up, The number of follicular keratotic papules were counted and the extent of perifollicular erythema and pigmentation was determined. At the same time, the participants provided subjective evaluations of treatment efficacy and safety.

RESULTS

This study was not registered.

Informed consent statement: All study participants, or their legal guardian, provided written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Data sharing statement: No additional data is available.

CONSORT 2010 statement: The manuscript was revised according to the CONSORT 2010 statement.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Specialty type: Dermatology

Country/Territory of origin: China

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

Received: January 26, 2021

Peer-review started: January 26, 2021

First decision: February 28, 2021

Revised: March 11, 2021

Accepted: April 22, 2021

Article in press: April 22, 2021

Published online: June 26, 2021

P-Reviewer: Carroll G

S-Editor: Wang JL

L-Editor: Filipodia

Treatment effectiveness was indicated by the percentage of keratotic papules in the test site, on days 20, 40, 60 and 80, which were 8%, 12%, 36%, and 60%, respectively. Compared with day 0, each difference was significant ($P < 0.05$). Compared with day 0, differences in melanin content (M) in the skin and skin lightness (L) on days 40, 60 and 80, the were statistically significant ($P < 0.05$); skin hemoglobin content (E) on days 60 and 80 was statistically different as compared with before treatment ($P < 0.05$). There were no significant differences in the number of keratotic papules, M, L, and E in 9 participants at the 5-year follow-up compared with before treatment ($P > 0.05\%$).

CONCLUSION

A high concentration of glycolic acid significantly improved skin roughness as well as follicular hyperpigmentation of patients with keratosis pilaris. The treatment was relatively safe, but there was no significant difference at the 5-year follow-up compared to before treatment.

Key Words: Keratosis pilaris; Glycolic acid; Keratotic papules; Follicular erythema; Melanin pigmentation

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: A high concentration of glycolic acid (50%, 70%) was applied to 25 subjects suffering from keratosis pilaris. The treatment was repeated every 20 d for a total of four times, 20 d after each treatment, perifollicular erythema, papules, and pigmentation were evaluated by spectrophotometry, counting and an Mexameter®. We found a high concentration of glycolic acid had a therapeutic effect on perifollicular erythema, papules and pigmentation, and as the number of treatments and the concentration of glycolic acid increased, the therapeutic effect improved further, but a long-term effect was not observed.

Citation: Tian Y, Li XX, Zhang JJ, Yun Q, Zhang S, Yu JY, Feng XJ, Xia AT, Kang Y, Huang F, Wan F. Clinical outcomes and 5-year follow-up results of keratosis pilaris treated by a high concentration of glycolic acid. *World J Clin Cases* 2021; 9(18): 4681-4689

URL: <https://www.wjgnet.com/2307-8960/full/v9/i18/4681.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v9.i18.4681>

INTRODUCTION

Keratosis pilaris is a hereditary abnormal keratosis of the hair follicular orifice. Clinically, gray-brown keratotic plugs in the pores and dark red keratotic papules at the openings of hair follicles that contain coiled hair and are often accompanied by perifollicular erythema and pigmentation can be seen. As mild or severe manifestations are present in more than half of the population, the condition can be understood as a normal variant, as opposed to a disease. However, because keratosis pilaris tends to affect exposed areas such as the face, extremities, and shoulder blades, with the highest incidence in adolescence[1], young people have a strong desire for treatment. Glycolic acid can correct abnormal hair follicular duct keratosis and eliminate excessive accumulation of keratinocytes. It can also promote skin metabolism and accelerate the metabolism of melanin. The therapeutic effect is related to the concentration of glycolic acid. We used a high concentration of glycolic acid to evaluate the efficacy and safety of glycolic acid in the treatment of keratosis pilaris, with long-term follow-up of 5 years.

MATERIALS AND METHODS

Subjects

All 25 subjects were clinically confirmed cases treated at the Dermatology Clinic of our

P-Editor: Yuan YY



hospital. They had typical rashes on their limbs or trunk, 7 were men and 18 were women. The average age was 27.2 ± 2.5 years and the average medical history was 18 ± 3.1 years.

Inclusion criteria: The limbs or trunk of eligible subjects had typical keratosis pilaris, with perifollicular erythema, papules, and pigmentation. No other treatment had been received within the last 6 mo. All subjects was willing to complete the study process and signed the informed consent form.

Exclusion criteria: Patients with serious underlying diseases, pregnancy, women with expected pregnancy or lactating, allergic to alpha hydroxy acid or sugar cane, being treated for localized healing wounds or other skin conditions, unable to guarantee they will not be using other exfoliant products or other treatment methods (including phototherapy and others) were excluded.

Exclusion and termination criteria: Subject withdrawal of informed consent; severe adverse reactions during the trial and termination of the treatment.

Treatment method

This was an open trial with a planned enrollment of 25 participants. After the attending physician assessed the skin lesions, an area with typical skin lesions was selected and a circular area delineated ($d = 8$ cm, $S = 50$ cm²). A high concentration of glycolic acid (Kunming Botanee Biological Technology Co., Ltd., Yunnan Food and Drug Administration License No. 20150002) was used for treatment for a total of four times, with an interval of 20 d, on days 0, 20, 40, and 60. The concentration and treatment duration were, 50%, 5 min; 50%, 7 min; 70%, 5 min; 70%, 7 min. Following each treatment, a neutralizing solution was sprayed evenly onto the application area until no further irritation was found at the test site. Following the procedure, the patient was advised to avoid light exposure to the area for a week. Those who completed the entire trial were considered valid cases, and those who did not complete the entire trial process for any reason were considered invalid cases.

Evaluation criteria for improvement of symptoms

Determination of the number of follicular keratotic papules: Before each treatment and 20 d after the last treatment, that is, on day 0, 20, 40, 60 and 80, the same dermatologist examined the test sites and counted the number of follicular keratotic papules (overall, $d = 8$ cm, $S = 50$ cm², in a circular area). A 0%-25% reduction in the number of papules was considered ineffective. A 26%-50% reduction in the number of papules was considered an improvement. A 51%-75% reduction in the number of papules was considered as obvious improvement, and a 76%-100% reduction in the number of papules was considered as excellent improvement.

Standardized evaluation of noninvasive skin testing: Before each treatment, 20 d after the last treatment, and 5 year after treatment, that is, on days 0, 20, 40, 60, 80 at the 5-year follow-up, the melanin content (M) and skin hemoglobin of the erythema and pigmentation of the hair follicular orifice was determined by a pigment measuring instrument (Mexameter, CK, Germany), and a spectrophotometer (CM-2600d, Konica Minolta, Japan) was used to measure skin lightness (L). Measurements were repeated three times in each area and the average value was taken. The M value reflects the melanin content in the skin, the E value indicates the degree of redness of the skin, and the L value indicated the balance between white and black. Pure black is 0 and pure white is 100.

Global esthetic improvement scale: Before each treatment, 20 days after the last treatment, and at 5 years after treatment, that is, on days 0, 20, 40, 60, 80 at the 5-year follow-up, the Global aesthetic improvement scale (Table 1) was used by subjects for self-assessment.

Statistical analysis

Before and after comparison of the number of keratotic papules per unit area ($S = 50$ cm²), the M, E, and L values was carried out using the paired *t*-test.

Table 1 Global esthetic improvement scale

Grading	Description
Excellent improvement	The best aesthetic results are achieved after treatment
Significant improvement	There is significant improvement in appearance compared to the initial situation
Some improvement	Compared with the initial situation, there is obvious improvement
No improvement	The appearance is essentially the same as the initial situation
Worse	The appearance is worse than the initial situation

RESULTS

Clinical evaluation

The number of follicular keratotic papules: The number of follicular orifice keratotic papules was monitored. On days 0, 20, 40, 60, and 80, the number of follicular keratotic papules was 53.12 ± 18.49 , 43.04 ± 17.53 , 36.92 ± 16.24 , 28.72 ± 13.51 , 22.16 ± 11.61 , respectively. The differences in the numbers of keratotic papules of days 20, 40, 60 and 80, compared to before treatment were significant. Moreover, the differences between each treatment were significant. On day 20, there were 2 cases of obvious improvement in the tested sites, 5 cases of improvement, and 10 cases of no effect. On day 40 (20 d after the second round of treatment), there was excellent improvement in 3 cases, improvement in 12 cases, and no effect in 10 cases. On day 60 (20 d after the third round of treatment), there was complete improvement in 1 case, excellent improvement in 8 cases, improvement in 13 cases, but no effect in 3 cases. On day 80 (20 d after the third round of treatment), there was complete improvement in 2 cases, excellent improvement in 13 cases, improvement in 8 cases, and no effect in 2 cases (Table 2, Figures 1 and 2).

The rate of effectiveness was calculated by dividing the summed number of cases with complete improvement, excellent improvement, and those with improvement by the overall total number of cases. The paired *t*-test was used to compare the number of keratotic papules before and after treatment, and the differences in the number of keratotic papules with improvement on days 20, 40, 60, and 80 were significant (Table 2, $P < 0.05$).

The number of keratotic papules on days 20, 40, 60 and 80 were compared with the number on day 0 and whether the differences between each treatment (*i.e.* whether the differences between days 40, 60, 80 and day 20; between days 60, 80, and day 40; and between days 80 and 60) were significant.

Standardized evaluation of noninvasive skin testing

The M and E values at the hair follicle orifice of the test site were determined before treatment and on days 20, 40, 60, and 80. The L values were measured by a spectrophotometer, repeated three times at each site, and the average value was taken for statistical analysis. The M values on days 40, 60, and 80 were significantly different compared with the value before treatment ($P < 0.05$). The E values on days 60 and 80 were significantly different compared with the value before treatment ($P < 0.05$). The L values on days 40, 60, and 80 were significantly different compared with the value before treatment ($P < 0.05$, Table 3). Nine subjects were followed-up at 5 years. Some subjects had left Beijing for work or study and some had changed their contact information. Six subjects were able to return to the outpatient clinic for photographs and measurement of M, E, and L values. There were no significant differences compared with the pretreatment values (Table 3).

Subject self-assessment

After the first round of treatment, on day 20, 2 subjects reported significant improvement, 9 reported some improvement, and 12 reported no change. On day 40, 4 subjects reported significant improvement, 11 reported some improvement, and 10 reported no change. On day 60, 1 subject reported excellent improvement, 5 reported significant improvement, 12 reported some improvement, and 7 reported no change. On day 80, 1 case reported excellent improvement, 7 reported significant improvement, 11 reported some improvement, and 6 reported no change. There were no cases of deterioration during treatment. At the 5-year follow-up, 3 cases reported some improvement, 4 cases reported no change, and 2 cases reported a deterioration in their

Table 2 Changes in the number of keratotic papules before and after treatment of the 25 study cases

Case	Day 0	Day 20	Day 40	Day 60	Day 80
1	52	25	20	16	10
2	26	22	21	15	14
3	95	80	71	58	28
4	46	38	32	25	24
5	58	49	33	29	21
6	35	23	19	14	10
7	80	58	43	37	26
8	66	47	58	23	19
9	35	21	18	15	11
10	75	59	50	38	36
11	38	25	16	15	12
12	43	37	33	26	13
13	55	53	48	43	42
14	61	30	22	15	11
15	48	45	41	31	25
16	57	55	51	45	43
17	39	33	28	21	14
18	72	65	55	43	37
19	28	22	19	12	7
20	30	27	21	16	12
21	42	38	33	27	23
22	58	53	45	37	29
23	65	62	57	49	33
24	36	29	23	16	9
25	88	80	66	52	45
Average	53.12 ± 18.49	43.04 ± 17.53	36.92 ± 16.24	28.72 ± 13.51	22.16 ± 11.61

Data are the number of keratotic papules before treatment and on days 20, 40, 60, and 80.

Table 3 Changes in melanin content, skin hemoglobin content, and skin lightness before and after treatment

Measurement index	Pretreatment	Day 20	Day 40	Day 60	Day 80	5 yr
M value	219.48 ± 64.09	215.80 ± 63.87	213.12 ± 60.42 ¹	203.92 ± 58.62 ¹	197.04 ± 59.23 ¹	223.56 ± 45.51
E value	261.76 ± 60.31	256.16 ± 64.00	258.48 ± 67.86	248.36 ± 62.50 ¹	242.2 ± 66.39 ¹	255.13 ± 51.25
L value	61.41 ± 4.23	61.94 ± 4.17	62.20 ± 3.94 ¹	62.57 ± 3.78 ¹	63.24 ± 3.60 ¹	61.89 ± 3.83

¹*P* < 0.05 vs pretreatment. E: Skin hemoglobin content; L: Skin lightness; M: Melanin content.

condition (Table 4).

Safety evaluation

The subjects were tolerant of high concentrations of glycolic acid. All 25 completed the 80-d study; no subjects dropped out. Only 1 subject experienced burning, itching, and discomfort when treated with 70% glycolic acid. The symptoms disappeared after treatment with the neutralizing solution. There was no irritation, skin sensitivity, or

Table 4 Self-evaluation status of subjects

	Day 20	Day 40	Day 60	Day 80	5 yr
Excellent improvement	0	0	1	1	0
Significant improvement	2	4	5	7	0
Some improvement	9	11	12	11	3
No change	12	10	7	6	4
Worse	0	0	0	0	2
Total	25	25	25	25	9

Data are the number of subjects.




Figure 1 Effectiveness of keratotic papule treatment. A: Day 20 of treatment; B: Day 40 of treatment; C: Day 60 of treatment; D: Day 80 of treatment. CI: Complete improvement; EI: Excellent improvement; ER: Effective rate; NI: No improvement; SI: Some improvement.



Figure 2 Therapeutic outcomes of a representative subject. A: Pretreatment; B: Day 20 of treatment; C: Day 40 of treatment; D: Day 60 of treatment; E: Day 80 of treatment.

crusting after the procedure.

Follow-up at 5 years

After 5 years, we were only able to contact 9 of the subjects (6 males and 3 females). Six

of them (3 males and 3 females) returned to the outpatient clinic for measurements and photographs, and the other 3 were followed-up by telephone. It was found that after 5 year, neither the number of follicular papules nor the M, E, and L values were significantly different from those before treatment (Table 3). Three patients (2 males and 1 female) reported that they felt less self-conscious than before. Two patients (1 male and 1 female) reported that they were worse than before treatment, and 4 patients (3 males and 1 female) did not notice any changes in the skin lesions (Table 4).

DISCUSSION

Keratosis pilaris is a chronic abnormal hair follicle keratosis. It is a cosmetic condition and does not affect physical health. Therefore, the need for treatment depends on the individual's wishes. As part of traditional treatment, people with extensive and severe skin rashes can take large doses of vitamin A or isotretinoin to relieve symptoms, but long-term large amounts of oral vitamin A may be toxic, and oral isotretinoin is not suitable for women who are planning pregnancy soon because of the risk of teratogenicity. Topical tretinoin[2] to regulate and control keratinization or topical exfoliants such as salicylic acid and lactic acid are often slow in their effects, and are associated with poor patient compliance, frequent relapse. Long-term use may lead to skin redness, desquamation, and itching. Apart from those therapies, laser treatment has also been used for the treatment of keratosis pilaris[3]. However, it is generally only effective for erythema and pigmentation around the hair follicle and not effective for hair follicle papules. There are currently no laser therapies that can treat papules, erythema and pigmentation of keratosis pilaris at the same time. In addition, laser treatment has disadvantages of obvious pain, long recovery time, high cost, and long treatment cycles[4].

Glycolic acid is a weak acid that interferes with the binding force on the cell surface, reduces adhesion and keratin accumulation in keratinocytes, accelerates the renewal and shedding of epidermal cells, enables smooth flow in the hair follicle infundibulum[5], stimulates the production of collagen to increase the water content of the skin, brightens the complexion, and reduces skin spots. At present, most reports on the treatment of keratosis pilaris with alpha hydroxyl acid describe its use in combination with other treatments[6], and the methods of efficacy evaluation involves single elements[7,8]. We evaluated efficacy from multiple perspectives, including papules, erythema, and pigmentation. In addition, a spectrophotometer was used innovatively for color analysis, and the L*a*b color system of the Commission Internationale de l'Eclairage was used to evaluate therapeutic effects[9,10]. The L value is primarily affected by melanin content. The higher the melanin content, the smaller the L value. In that respect, it is similar to the M value, and consistent changes in both values confirms changes in melanin levels. The E value is primarily influenced by hemoglobin, and reflects the degree of redness in the skin around the hair follicle orifice. The redder the skin, the higher the E value. It is a quantitative measurement of color that is less affected by subjective factors, and has good comparability and repeatability.

In this study, it was found that the treatment of keratosis pilaris with a high concentration of glycolic acid alone had a therapeutic effect on keratotic papules after the first treatment. Treatment efficacy gradually improved with the increase in the number of treatments and the therapeutic concentration. A concentration of 70% glycolic acid achieved 92% effectiveness after four treatment cycles. A high concentration of glycolic acid had a therapeutic effect on perifollicular pigmentation after the second treatment, with a decrease in M value and an increase in L value. As the number of treatments and the treatment concentration increased, the therapeutic effect improved further. At the same time, a high concentration of glycolic acid was also effective in the treatment of perifollicular erythema, but the improvement appeared later than the reduction in the number of follicular keratotic papules and the improvement of perifollicular pigmentation, with the effects appearing after the third treatment. Once again, an increase in the number of treatments resulted in further improvement. The treatment was safe and well tolerated during the study period. Only 1 subject experienced burning and itching discomfort during the procedure. At the same time, the level of subjective satisfaction of the participants was high, with 76% of the subjects (19 of 25) reporting an improvement after completing four treatments.

CONCLUSION

The treatment process was simple and the effects were observed soon after application. After the first treatment, 44% of the subjects (11 of 25) reported improvement. There were no obvious adverse reactions, and the level of patient acceptance was high. This study proved that a high concentration of glycolic acid was a safe and efficacious treatment for keratosis pilaris, and that improvement was achieved rapidly. After 5 year, we conducted follow-up of the subjects who accepted the treatment, and a long-term therapeutic effect of a high concentration of glycolic acid in the treatment of keratosis pilaris was not observed.

ARTICLE HIGHLIGHTS

Research background

The incidence of keratosis pilaris is high, and although there are many treatments, the results usually do not persist.

Research motivation

Keratosis pilaris affects the appearance of patients; Glycolic acid can improve the texture and color of the skin.

Research objectives

We followed subjects for 5 year, which allowed evaluation of both short-term and long-term efficacy of high-concentration glycolic acid for treating periceratosis.

Research methods

We used spectrophotometry and the L*a*b color system as an innovative evaluation of both the treatment effects and the color and luster of the lesions.

Research results

Compared with pretreatment values, differences in the number of keratotic papules, melanin content, skin lightness, and skin hemoglobin on days 20, 40, 60, and 80 were significant. The differences were not significant at the 5-year follow-up.

Research conclusions

A high concentration of glycolic acid significantly improved skin roughness as well as follicular hyperpigmentation in patients with keratosis pilaris. The treatment was relatively safe, but there was no significant difference at the 5-year follow-up compared with pretreatment values.

Research perspectives

High-concentration glycolic acid can be used as a novel treatment for keratosis pilaris.

REFERENCES

- 1 **Zhao B.** Clinical Dermatology. Jiangsu: Jiangsu Science and Technology Press, 2012: 793-794
- 2 **Zhao JB.** Treatment of keratosis pilaris with tretinoin cream. *Zhonghua Pifuke Zazhi* 2004; **37**: 631
- 3 **Jiang L,** Tu P, Tan YH, Shu XF, Zhang C, Li M, Han Y. Clinical efficacy of 810nm semiconductor laser in the treatment of keratosis pilaris. *Zhonghua Yixue Meixu Meirong Zazhi* 2015; **21**: 226-228
- 4 **Lee SJ,** Choi MJ, Zheng Z, Chung WS, Kim YK, Cho SB. Combination of 595-nm pulsed dye laser, long-pulsed 755-nm alexandrite laser, and microdermabrasion treatment for keratosis pilaris: retrospective analysis of 26 Korean patients. *J Cosmet Laser Ther* 2013; **15**: 150-154 [PMID: 23464682 DOI: 10.3109/14764172.2013.769276]
- 5 **Yu RJ.** Discover and development of alpha hydroxyl acids and polyhydroxy acids for use in various dermatological condition. *Inter Cong Dermatol* 2004; 35
- 6 **Zeng BB,** Yang T, Li JJ, Lu WJ, Wang LM, Zhang J, Lin XX. Clinical observation of keratosis pilaris treated with glycolic acid and retinoid cream. *Zhongguo Meirong Yixue* 2014; **23**: 1988-1989
- 7 **Gao L,** Chen Y, Gao TW, Wang G. Experience of tartaric acid in the treatment of keratosis pilaris. *Zhongguo Jiguang Yixue Zazhi* 2012; **21**: 328
- 8 **Feng KN.** Outcomes of keratosis pilaris treated by glycolic acid. *Zhongguo Meirong Yixue* 2013; **22**: 2220-2221

- 9 **Li W**, Li MS, Guo GZ. Quantitative measurement of skin color. *Zhongguo Zhengxing Waike Zazhi* 2002; **18**: 111-113
- 10 **Alaluf S**, Atkins D, Barrett K, Blount M, Carter N, Heath A. The impact of epidermal melanin on objective measurements of human skin colour. *Pigment Cell Res* 2002; **15**: 119-126 [PMID: 11936269 DOI: 10.1034/j.1600-0749.2002.16072.x]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

